References
Lyseng-Williamson KA, Goa K. Linezolid: in infants and children with severe gram-positive infections. Pediatric Drugs 2003; 5(6): 419–29
Deville JG. Linezolid in infants and children with severe gram-positive infections: a viewpoint. Pediatric Drugs 2003; 5(6): 430
Amsden GW. Linezolid in infants and children with severe gram-positive infections: a viewpoint. Pediatric Drugs 2003; 5(6): 430–1
Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo (MI), 2002 Dec
Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132–6
Kaplan SL, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Linezolid versus vancomycin in the treatment of resistant Gram-positive infections in children [poster no. 642]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24–27; Chicago
Bruss JB, Fleishaker DL, Naberhuis-Stehouwer S, et al. Linezolid vs cefadroxil in the treatment of skin and skin structure infections in children [abstract no. 1596]. Pediatr Res 2002 Apr; 51 (4 Pt 2): 274A plus poster presented at the Annual Meeting of the Pediatric Academic Societies; 2002 May 4–7; Baltimore
Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001 May; 20(5): 488–94
Rights and permissions
About this article
Cite this article
Linezolid in infants and children with severe Gram-positive infections: profile report. Drugs Ther. Perspect 19, 6–8 (2003). https://doi.org/10.2165/00042310-200319090-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200319090-00003